natgillin/translations-raw huggingface dataset:
The efficacy of the components of the previous formulation of the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. was established in a series of double-blind controlled field trials, which demonstrated a high degree of protective efficacy afforded by the individual vaccine components.
Djelotvornost sastavnih cjepiva prethodnog kombiniranog cjepiva protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc. bila je utvrđena u nizu dvostruko slijepih kontroliranih terenskih ispitivanja, koja su pokazala visok stupanj zaštitne djelotvornosti koju su pružala pojedinačna cjepiva.
The efficacy of vortioxetine is supported by the pooled responder analysis, in which the proportion of responders ranged from 46% to 49% for vortioxetine versus 34% for placebo (p &lt; 0.01; NRI analysis).
Djelotvornost vortioksetina je podržana objedinjenom analizom onih koji su odgovorili na liječenje u kojoj je udio onih koji su odgovorili bio u rasponu od 46% do 49% za vortioksetin u usporedbi s 34% za placebo (p &lt; 0,01; NRI analiza).
The efficacy of Xeristar 30-120 mg (flexible dosing) once a day in elderly patients ( &gt; 65 years) with generalised anxiety disorder was evaluated in a study that demonstrated statistically significant improvement in the HAM-A total score for duloxetine treated patients compared to placebo treated patients.
Djelotvornost lijeka Xeristar u dozi od 30-120 mg (fleksibilno doziranje) jednom dnevno u starijih bolesnika ( &gt; 65 godina) s generaliziranim anksioznim poremećajem ocijenjena je u ispitivanju koje je pokazalo statistički značajno poboljšanje ukupnog broja bodova na HAM A ljestvici u bolesnika liječenih duloksetinom u odnosu na one koji su uzimali placebo.
The ESTIMABL study randomised 752 patients with low-risk thyroid cancer (tumour stages pT1 &lt; 1 cm and N1 or Nx, pT1 &gt; 1-2 cm and any N stage, or pT2 N0, all patients M0) at 24 centres.
U ispitivanju ESTIMABL randomizirana su 752 bolesnika s tumorom štitnjače niskog rizika (stadiji tumora pT1 &lt; 1 cm i N1 ili Nx, pT1 &gt; 1-2 cm i bilo koji stadij N ili pT2 N0, svi bolesnici M0) u 24 centra.
The estimated 3-year probability of having pneumonia reported as an adverse event was 12.3% for placebo, 13.3% for salmeterol, 18.3% for FP and 19.6% for salmeterol/fluticasone propionate (hazard ratio for fluticasone propionate/salmeterol vs placebo: 1.64, 95% CI: 1.33 to 2.01, p &lt; 0.001).
Procijenjena trogodišnja vjerojatnost razvoja pneumonije koja se prijavljivala kao štetni događaj iznosila je 12,3% za placebo, 13,3% za salmeterol, 18,3% za FP i 19,6% za salmeterol/flutikazonpropionat (omjer hazarda za flutikazonpropionat/salmeterol naspram placeba: 1,64, 95% CI: 1,33 do 2,01, p &lt; 0,001).
The estimated rate of patients free of progression to accelerated phase or blast crisis at 84 months was significantly higher in the Glivec arm compared to the IFN arm (92.5% versus 85.1%, p &lt; 0.001).
Procijenjena stopa bolesnika bez progresije u ubrzanu fazu ili blastičnu krizu nakon 84 mjeseca bila je značajno viša u Glivec kraku u usporedbi s IFN krakom (92,5% prema 85,1%, p &lt; 0,001).
The estimated rate of patients free of progression to accelerated phase or blast crisis at 84 months was significantly higher in the imatinib arm compared to the IFN arm (92.5% versus 85.1%, p &lt; 0.001).
Procijenjena stopa bolesnika bez progresije u ubrzanu fazu ili blastičnu krizu nakon 84 mjeseca bila je značajno viša u kraku koji je primao imatinib u usporedbi s krakom koji je primao IFN (92,5% prema 85,1%, p &lt; 0,001).
The estimated rate of progression-free survival at 84 months was 81.2% in the Glivec arm and 60.6% in the control arm (p &lt; 0.001).
Procijenjena stopa preživljenja bez progresije nakon 84 mjeseca bila je 81,2% u Glivec kraku i 60,6% u kontrolnom kraku (p &lt; 0,001%).
The estimated rate of progression-free survival at 84 months was 81.2% in the imatinib arm and 60.6% in the control arm (p &lt; 0.001).
Procijenjena stopa preživljenja bez progresije nakon 84 mjeseca bila je 81,2% u kraku koji je primao imatinib i 60,6% u kontrolnom kraku (p &lt; 0,001%).
The European Commission granted a marketing authorisation valid throughout the European Union for Duloxetine Lilly on 8 December 2014.
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Duloxetine Lilly na snazi u Europskoj uniji od &lt; datum izdavanja odobrenja za stavljanje u promet &gt; .
The European Commission granted a marketing authorisation valid throughout the European Union for Mirvaso on 21 February 2014.
Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek &lt; X &gt; vrijedi na prostoru Europske unije od 21. veljače 2014.
The European Commission granted a marketing authorisation valid throughout the European Union for Sirturo on 05/03/2014.
Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek Sirturo vrijedi na prostoru Europske unije od &lt; datum izdavanja odobrenja za stavljanje u promet &gt; .
The European Commission granted a marketing authorisation valid throughout the European Union for Zurampic on 18 February 2016.
Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek Zurampic vrijedi na prostoru Europske unije od &lt; datum izdavanja odobrenja za stavljanje u promet &gt; .
The European Medicines Agency has deferred the obligation to submit the results of studies with Zinforo in the paediatric population aged birth to &lt; 2 months (see section 4.2 for information on paediatric use).
Europska agencija za lijekove je odgodila obvezu podnošenja rezultata ispitivanja lijeka Zinforo u pedijatrijskoj populaciji u dobi od rođenja do &lt; 2 mjeseca (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
The European Medicines Agency has waived the obligation to submit the results of studies with BUCCOLAM in the subset of the paediatric population &lt; 3months old, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for these paediatric patients.
Europska agencija za lijekove je izuzela obvezu podnošenja rezultata ispitivanja lijeka BUCCOLAM u svim podskupinama pedijatrijske populacije mlađe od 3 mjeseca, uz obrazloženje da ovaj specifični lijek ne predstavlja značajnu terapijsku korist pred postojećim načinima liječenja tih pedijatrijskih bolesnika.
The experience in patients &gt; 65 years and in patients with impaired renal function is limited.
Iskustva s bolesnicima starijima od 65 godina te onima s oštećenom funkcijom bubrega su oskudna.
The exploratory analyses of covariates with information in only a subset of patients suggested that patients with greater shed HER2-ECD level had faster nonlinear clearance (lower Km) (P  0.001).
Eksploracijske analize kovarijanti na temelju podataka prikupljenih samo u jednoj podskupini bolesnika pokazali su da su bolesnici s višom razinom odcjepljivanja HER2-ECD-a imali brži nelinearni klirens (niži Km) (P &lt; 0,001).
The film-coated tablet (tablet) is a, oval, biconvex, brick red coloured 19.3 x 9.3 mm tablet with bevelled edges and the inscription 145/40 on one side and the Abbott logo on the other side.
Filmom obložena tableta (tableta) je ovalna, bikonveksna, ciglasto crvena tableta veličine 19,3 x 9,3 mm s kosim rubovima i oznakom 145/40 na jednoj strani i logotipom Abbott na drugoj strani.
The film-coated tablet (tablet) is a, oval, biconvex, tan coloured 19.3 x 9.3 mm tablet with bevelled edges and the inscription 145/20 on one side and the Abbott logo on the other side.
Filmom obložena tableta (tableta) je ovalna, bikonveksna, žućkastosmeđa tableta veličine 19,3 x 9,3 mm s kosim rubovima i oznakom 145/20 na jednoj strani i logotipom Abbott na drugoj strani.
The findings for the key secondary efficacy endpoint, a 3-year K-M event rate of 9.3% in the Zontivity group compared with that of 10.5% in placebo group (HR: 0.87; 95% CI, 0.80 to 0.94; p &lt; 0.001).
Rezultati ključne mjere sekundarnog ishoda za djelotvornost pokazuju da je 3-godišnja stopa događaja po Kaplan-Meieru iznosila 9,3% u skupini liječenoj lijekom Zontivity naspram 10,5% u skupini koja je primala placebo (HR: 0,87; 95% CI, 0,80 do 0,94; p &lt; 0,001).
The following additional adverse reactions suspected to be immune-related have been reported in &lt; 2% of patients treated with ipilimumab 3 mg/kg monotherapy: uveitis, eosinophilia, lipase elevation, and glomerulonephritis.
Sljedeće dodatne nuspojave za koje se vjeruje da su imunološki uzrokovane zabilježene su u &lt; 2% bolesnika liječenih monoterapijom ipilimumabom u dozi od 3 mg/kg: uveitis, eozinofilija, povišena razina lipaze i glomerulonefritis.
The following adverse reactions are classified according to the following convention: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), or not known (cannot be estimated from available data).
Niže navedene nuspojave razvrstane su na sljedeći način: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), ili nepoznato (ne može se procijeniti iz dostupnih podataka).
The following adverse reactions have been reported during clinical studies and post-marketing data and are classified according to the following convention: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1000)very rare ( &lt; 1/10,000) or not known (cannot be estimated from the available data).
Niže navedene nuspojave zabilježene su u kliničkim ispitivanjima i praćenju nakon stavljanja lijeka u promet i razvrstane su prema sljedećoj učestalosti: vrlo često (≥ 1/10), često (≥1/100 do 1≤1/10), manje često (≥1/1000 do ≤1/100), rijetko (≥1/10 000 do ≤1/1000), vrlo rijetko (≤1/10 000) ili nepoznato (ne može se procijeniti iz dostupnih podataka).
The following adverse reactions have been reported with brinzolamide 10mg/ml eye drops, suspension and are classified according to the following convention: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1000), very rare ( &lt; 1/10,000), or not known (cannot be estimated from the available data).
Niže navedene nuspojave zabilježene su s brinzolamidom 10 mg/ml kapi za oko, suspenzijom i razvrstane su prema sljedećoj učestalosti: vrlo često (≥1/10), često (≥1/100 do &lt; 1/10), manje često (≥1/1000 do &lt; 1/100), rijetko (≥1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000) ili nepoznato (ne može se procijeniti iz dostupnih podataka).
The following adverse reactions have been reported with pitolisant during clinical studies enrolling more than 1094 patients in narcolepsy and other indications and are listed below as MedDRA preferred term by system organ class and frequency; frequencies are defined as: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000); within each frequency group, adverse reactions are presented in order of decreasing seriousness:
Tijekom kliničkih ispitivanja s pitolizantom u kojima je sudjelovalo više od 1094 bolesnika s narkolepsijom i drugim indikacijama, zabilježene su nuspojave navedene u nastavku prema preporučenim izrazima MedDRA-e, klasificirane po organskim sustavima i učestalosti; učestalost je definirana kao: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000); unutar svake skupine učestalosti, nuspojave su prikazane redoslijedom prema padajućoj ozbiljnosti.
The following adverse reactions in retroperitoneal or intra-abdominal surgery and in neurosurgery was common (defined as ≥ 1/100, &lt; 1/10).
Sljedeće nuspojave pri retroperitonealnim ili intraabdominalnim kirurškim i neurokirurškim zahvatima bile su česte (definirano kao ≥ 1/100, &lt; 1/10).
The following adverse reactions were assessed to be related with Travoprost 40 µg/mL eye drops, solution (either BAK or Polyquad- preserved) and are classified according to the following convention: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000) and not known (cannot be estimated from the available data).
Sljedeće su nuspojave povezane s Travoprost 40 µg/ml kapima za oko, otopinom (bilo BAK ili polikvad–konzervans) i razvrstane su prema slijedećem dogovoru: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000) ili nepoznato (ne može se procijeniti iz dostupnih podataka).
The following adverse reactions were reported in controlled clinical studies at the recommended dose of 2 mg with frequencies corresponding to very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000) and very rare ( &lt; 1/10,000) and not known (cannot be estimated from available data).
Sljedeće nuspojave zabilježene su u kontroliranim kliničkim ispitivanjima preporučene doze od 2 mg učestalošću koja odgovara sljedećim kategorijama: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000) i vrlo rijetko ( &lt; 1/10 000), te nepoznato (ne može se procijeniti iz dostupnih podataka).
The following adverse reactions were reported in controlled clinical studies at the recommended dose of 2 mg with frequencies corresponding to very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000) and very rare ( &lt; 1/10,000) and not known (cannot be estimated from the available data).
Sljedeće nuspojave zabilježene su u kontroliranim kliničkim ispitivanjima preporučene doze od 2 mg učestalošću koja odgovara sljedećim kategorijama: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000) i vrlo rijetko ( &lt; 1/10 000), te nepoznato (ne može se procijeniti iz dostupnih podataka).
The following age groups will be used: &lt; 2 years, 2-8 years,
Koristit će se sljedeće dobne skupine: &lt; 2 godine, 2-8 godina,
The following age groups will be used: &lt; 2 years, 2-8 years, &gt; 9 years.
Rabit će se sljedeće dobne skupine: &lt; 2 godine, 2-8 godina, &gt; 9 godina.
The following categories are used to rank the adverse reactions by frequency of occurrence: very common ( ≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); and very rare ( &lt; 1/10,000), including isolated reports.
S obzirom na učestalost javljanja, nuspojave su razvrstane po slijedećim kategorijama: vrlo čest≥e 1(/10); česte (≥1/100 i &lt; 1/10); manje česte (≥1/1.000 i &lt; 1/100); rijetke (≥ 1/10.000 i &lt; 1.000) i vrlo rijetke ( &lt; 1/10.000) uključujući pojedinačne slučajeve.
The following categories are used to rank the adverse reactions by frequency of occurrence: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to
Sljedeće kategorije korištene su za svrstavanje nuspojava prema učestalosti pojavljivanja: vrlo često (≥ 1/10); često (≥ 1/100 do &lt; 1/10); manje često (≥ 1/1000 do &lt; 1/100); rijetko (≥ 1/10 000 do
The following common or uncommon adverse reactions were reported for palonosetron, none were reported at a frequency of &gt; 1%.
Sljedeće nuspojave su prijavljene kao česte i manje česte tijekom primjene palonosterona, nije bilo prijavljenih s učestalošću &gt; 1%.
The following common or uncommon adverse reactions were reported for palonosetron, none were reported at a frequency of &gt; 1%.
Sljedeće česte ili manje česte nuspojave zabilježene su za palonozetron, pri čemu nijedna nije zabilježena uz učestalost od &gt; 1 %.
The following convention has been used for the classification of adverse reactions: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100).
Primijenila se sljedeća konvencija za klasifikaciju nuspojava: vrlo često (≥1/10), često (≥1/100 i &lt; 1/10), manje često (≥1/1000 i &lt; 1/100).
The following convention has been used for the classification of frequencies: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
Za određivanje učestalosti korištene su sljedeće kategorije: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
The following convention has been used for the classification of the adverse reactions (see table 1): very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000) and very rare ( &lt; 1/10,000).
Sljedeća je razdioba korištena za klasifikaciju nuspojava (vidjeti tablicu 1): vrlo česte ( ≥ 1/10), česte (≥ 1/100 do &lt; 1/10), manje česte (≥ 1/1000 do &lt; 1/100), rijetke (≥ 1/10 000 do &lt; 1/1000) i vrlo rijetke ( &lt; 1/10 000).
The following convention has been used for the classification of the adverse reactions based on incidence rates in three phase III and two phase II clinical studies (see table 1): very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000) and very rare ( &lt; 1/10,000).
Za klasifikaciju nuspojava temeljenih na stopi incidencija u tri klinička ispitivanja faze III i dva klinička ispitivanja faze II (vidjeti tablicu 1) korištena je sljedeća klasifikacija: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1 000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1 000) i vrlo rijetko ( &lt; 1/10 000).
The following convention has been used for the classification of the adverse reactions: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000).
Unutar svake grupe učestalost nuspojave klasificirana je na sljedeći način: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000).
The following convention has been used for their classification: very common ( &gt; 1/10), common ( &gt; 1/100 to &lt; 1/10), uncommon ( &gt; 1/1,000 to &lt; 1/100), rare ( &gt; 1/10,000 to &lt; 1/1,000) very rare ( &lt; 1/10,000).
Klasificirane su prema učestalosti: vrlo često ( &gt; 1/10), često ( &gt; 1/100 do &lt; 1/10), manje često ( &gt; 1/1000 do &lt; 1/100), rijetko ( &gt; 1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000).
The following convention has been utilised for the classification of frequency: very common ((1/10), common (1/100 to &lt; 1/10), uncommon (1/1,000 to &lt; 1/100), rare (1/10,000 to &lt; 1/1,000) and very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Nuspojave su klasificirane na sljedeći način: vrlo često (≥1/10), često (≥1/100 do &lt; 1/10), manje često (≥1/1000 do &lt; 1/100), rijetko (≥1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se odrediti iz dostupnih podataka).
The following conventional classification is used: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Za to se koristila sljedeća uobičajena klasifikacija: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The following conventional classification is used: very common (≥1/10), common (≥1/100 to &lt; 1/10), uncommon (≥1/1,000 to &lt; 1/100), rare (≥1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Za to se koristila sljedeća uobičajena klasifikacija: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The following conventional classification is used: very common (1/10), common (1/100 to &lt; 1/10), uncommon (1/1,000 to &lt; 1/100), rare (1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Za to se koristila sljedeća uobičajena klasifikacija: vrlo često (1/10), često (1/100 i &lt; 1/10), manje često (1/1000 i &lt; 1/100), rijetko (1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The following conventional classification is used: very common 1/10), common 1/100 to &lt; 1/10), uncommon 1/1,000 to &lt; 1/100), rare ( 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
Za to se koristila sljedeća uobičajena klasifikacija: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The following examples assume the patient’s baseline factor X level is &lt; 1 IU/dL:
Sljedeći primjeri pretpostavljaju da je bolesnikova početna vrijednost razine faktora X &lt; 1 IU/dl:
The following groups were not well represented in clinical trials: elderly ( &gt; 75 years, 2.4%), and patients with certain cardiovascular conditions (see section 4.3).
Sljedeće skupine nisu bile dobro zastupljene u kliničkim ispitivanjima: stariji ( &gt; 75 godina, 2,4%) i bolesnici s određenim kardiovaskularnim bolestima (vidjeti dio 4.3).
The following headings are used to rank the ADRs by frequency: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10) uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000) and very rare ( &lt; 1/10,000).
Za klasifikaciju nuspojava prema učestalosti koriste se sljedeće oznake: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10) , manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1000) i vrlo rijetko ( &lt; 1/10 000).
The following headings are used to rank the ADRs by frequency: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000).
Za klasifikaciju nuspojava prema učestalosti koriste se sljedeće oznake: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1,000, do &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000).
The following headings are used to rank the ADRs by frequency: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000).
Za klasifikaciju nuspojava prema učestalosti koriste se sljedeće oznake: vrlo često (≥ 1/10), često (≥ 1/100 do &lt; 1/10), manje često (≥ 1/1000 do &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000).
The following headings are used to rank the ADRs by frequency: very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000).
Za klasifikaciju nuspojava prema učestalosti koriste se sljedeće oznake: vrlo često (≥ 1/10), često (≥ 1/100, &lt; 1/10), manje često (≥ 1/1000, &lt; 1/100), rijetko (≥ 1/10 000, &lt; 1/1000) i vrlo rijetko ( &lt; 1/10 000).
The following headings are used to rank the ADRs by frequency: very common ( 1/10), common ( 1/100 to &lt; 1/10), uncommon ( 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000).
Za klasifikaciju nuspojava prema učestalosti koriste se sljedeće oznake: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000).